The highly aggressive muscle cancer alveolar rhabdomyosarcoma (ARMS) is one of the most common soft tissue sarcoma of childhood, yet the outcome for the unresectable and metastatic disease is dismal and unchanged for nearly three decades. To better understand the pathogenesis of this disease and to facilitate novel preclinical approaches, we previously developed a conditional mouse model of ARMS by faithfully recapitulating the genetic mutations observed in the human disease, i.e., activation of Pax3:Fkhr fusion gene with either p53 or Cdkn2a inactivation. In this report, we show that this model recapitulates the immunohistochemical profile and the rapid progression of the human disease. We show that Pax3:Fkhr expression increases during late preneoplasia but tumor cells undergoing metastasis are under apparent selection for Pax3:Fkhr expression. At a whole-genome level, a cross-species gene set enrichment analysis and metagene projection study showed that our mouse model is most similar to human ARMS when compared with other pediatric cancers.
Introduction
Rhabdomyosarcoma is the most common soft tissue tumor in childhood (1) . Pediatric rhabdomyosarcoma can be divided into two major subtypes, embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma (ARMS; ref. 1) . ERMS comprises 50% to 60% of all rhabdomyosarcoma cases and typically manifests a favorable outcome, whereas 20% to 30% of rhabdomyosarcoma are of the more aggressive alveolar subtype that is associated with frequent metastasis at the time of initial diagnosis (2) . The development of more effective therapies in ARMS, however, has been hampered by a lack of knowledge about basic molecular mechanisms of tumor development. Cytogenetic and molecular studies show that 70% to 85% of ARMS have balanced chromosomal translocations of t(2;13) or t(1;13), which lead to the formation of chimeric transcription factors consisting of the NH 2 terminal regions of Pax3 or Pax7 fused to the COOH terminal region of Fkhr (3). Pax3:Fkhr-positive ARMS is more aggressive than Pax7:Fkhr-positive or fusion-negative ARMS; thus, Pax3:Fkhrpositive ARMS represents the most clinically intractable subset of ARMS (4) .
We previously generated a conditional knock-in allele of Pax3:Fkhr in Pax3 locus and established a mouse model of ARMS by simultaneously activating Pax3:Fkhr expression and inactivating p53 or Cdkn2a in Myf6-expressing maturing myofibers (5-7). In the current study, we show that this model authentically recapitulates the natural history, histologic features, and genetic features of the human disease, and we show the utility of this model in understanding the aspects of disease progression and therapeutic target identification.
Materials and Methods
Mice. The conditional models of ARMS have been previously described (5) . At necropsy, animals were sacrificed by CO 2 asphyxiation in accordance with an approved Institutional Animal Care and Use Committee protocol. Characteristics of mouse tumor and skeletal muscle samples used for microarray and quantitative reverse transcription-PCR (qRT-PCR) are described in Supplementary Tables S1 and S2 .
Real-time RT-PCR. qRT-PCR analyses were performed by a Taqman assay for mouse Pax3:Fkhr expression or by SYBR Green assay (PE Applied Biosystems) for other genes of interest. Primer and probe sequences are shown in Supplementary Tables S3 and S4 .
Gene expression analysis. Gene expression analysis was performed using Affymetrix Mouse 430A arrays (Affymetrix). Original CEL files of the mouse ARMS are uploaded in the Gene Expression Omnibus site.
14 For human tumors, published data sets of rhabdomyosarcomas (8, 9) , juvenile and old skeletal muscles (10) , Duchene muscular dystrophy (11) , and a series of mesenchymal tumors (12, 13) and pediatric malignancies (14) were used (Supplementary Table S5 CAT and luciferase reporter assays. CAT constructs containing SKP2 promoter were described previously (17) . The 220-bp genomic fragment 49-kb 3 ¶ to Skp2 gene was inserted into pGL4.24 vector (Promega). Reporter plasmids were cotransfected with Pax3:Fkhr and p53 into NIH3T3 cells or p53-deficient mouse embryonic fibroblasts (MEF).
Western blotting. Western blotting was performed as previously described (18) . Antibodies against p27Kip1 (C-19), Skp2 (H-435), and Fkhr (C-20) were from Santa Cruz. Pax3 antibody (ab-2) was from Geneka. a-Tubulin antibody was from Oncogene.
Results
Biallelic activation of Pax3:Fkhr and disruption of p53 or Cdkn2a are necessary for high penetrance of ARMS. The mean latency of ARMS development was 110 days with 100% penetrance of ARMS when biallelic activation of conditional Pax3:Fkhr allele was combined with homozygous deletion of conditional p53 allele (Fig. 1A) . However, when the mice had homozygous Pax3:Fkhr and heterozygous p53 mutant alleles or heterozygous Pax3:Fkhr and homozygous p53 mutant allele combinations, tumor incidence was significantly lower than that of double homozygous alleles (P < 0.001), indicating a mutation dosage effect. As previously described, activation of Pax3:Fkhr was necessary but not sufficient for ARMS development (5). When Pax3:Fkhr allele was combined with conditional Cdkn2a mutation, mice still required biallelic activation of both mutations to develop ARMS at 100% penetrance (Fig. 1B) . There was no significant difference in ARMS development between Pax3:Fkhr-p53 mice and Pax3:Fkhr-Cdkn2a mice (Fig. 1C) . All ARMS cases were diagnosed by a qualified pathologist based upon histology, as well as MyoD and Myogenin immunohistochemistry (Fig. 1D) P3Fm/P3Fm p53 F2-10/F2-10 mice (P < 0.001, log-rank test). These findings suggest that the tumors from Myf6
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P3Fm/P3Fm p53 F2-10/F2-10 mice are not caused solely by p53 mutation but by cooperating effects of Pax3:Fkhr and p53 mutation.
Conditional mouse models of ARMS share the aggressive features of the human disease. The sites of tumors and stages at necropsy are summarized in Supplementary Tables 7A and 7B . Both Pax3:Fkhr, p53 and Pax3:Fkhr, Cdkn2a models developed advanced ARMS tumors, although the frequency of distant hematogenous metastasis in Pax3:Fkhr, p53 model was significantly higher than in Pax3:Fkhr, Cdkn2a model (m 2 test, P < 0.0001). These conditional mouse models showed a predisposition to rapid disease progression, including rapid local tumor growth and invasion, regional lymph node involvement, and distant hematogenous metastasis ( Fig. 2A-D; Supplementary Table S7B ). For the latter, micro-CT scan showed both macrometastases and alveolar macrophages associated with micrometastases ( Fig. 2C and D) .
Transcriptional activation of Pax3:Fkhr is associated with ARMS progression. Although expression of Pax3:Fkhr fusion gene is driven by Pax3 promoter in both human ARMS and in our conditional mouse models, promoter activity of Pax3 is predicted to be low in mature myofibers (19 F2-10/F2-10 preneoplastic skeletal muscle was low, whereas Pax3:Fkhr expression was >100-fold higher in ARMS tumors. Metastatic tumors expressed Pax3:Fkhr at incrementally higher levels than the primary tumors. Pax3:Fkhr in the mouse tumor tissues were also detected at protein level using anti-Fkhr antibody (Fig. 3B) . We also performed immunofluorescent analysis of corresponding tissue samples using anti-GFP antibody as an in situ correlate of Pax3:Fkhr expression (Fig. 3C) . In our mice, Pax3:Fkhr is followed by an internal ribosomal entry site and the eYFP gene; therefore, eYFP expression corresponds to transcriptional activation of Pax3:Fkhr in these tissues (5) . Whereas eYFP was undetectable in WT and preneoplastic adolescent skeletal muscle, primary and metastatic ARMS tumors strongly expressed eYFP. Expression pattern of eYFP in primary tumors was heterogeneous compared with the uniform expression pattern in metastatic tumors; quantitatively, the number of eYFP-expressing cells in metastatic ARMS tumors was higher than primary tumors (90% versus 33%, P < 0.001). These results suggest that the level of the transcriptional activation of Pax3:Fkhr is linked to tumor development and progression and that cooperative cellular events are required in the transformation from preneoplasia to tumor to activate Pax3:Fkhr transcription. Later, higher quantitative Pax3:Fkhr levels by RT-PCR for metastatic tumor lesions seems to be attributable to the more uniform expression of Pax3:Fkhr in tumor cells, but not necessarily higher expression in any individual cell.
Cross-species comparison of molecular signatures validates the mouse model as representative of human ARMS. GSEA is a computational method, which has been successfully used to assess whether pathways are conserved between zebrafish and human rhabdomyosarcoma (20, 21) . For our GSEA, we tested whether the gene sets up-regulated in mouse ARMS are enriched in human ARMS when compared with other mesenchymal malignancies. The differentially expressed genes were selected by comparing mouse ARMS to 4-week-old WT skeletal muscle at P value of <0.01. Using published database of human sarcomas (13), we performed GSEA with up-regulated gene sets of mouse ARMS (list in Supplementary Table S8 ). The gene set up-regulated in mouse ARMS was enriched most significantly in human ARMS among all human mesenchymal malignancies (normalized enrichment score = 2.0720, FDR qval < 0.001; Supplementary Table S9) . ERMS scored lower (normalized enrichment score = 1.5773, FDR qval = 0.0038). Additional GSEA results using a human rhabdomyosarcoma data set (9) are given in Supplementary Fig. S2 .
Tamayo and colleagues recently developed a metagene projection methodology to enable a direct cross-species and crossplatform comparison (22) . This method can be used to assess the degree to which mouse ARMS displays a transcriptional profile comparable with other human tumors (15) . For the purpose of further investigating whether mouse ARMS shares genetic features of human ARMS, metagene projection analysis was undertaken. To define a metagene for human ARMS compared with other human tumors, we used previously published data sets of human mesenchymal tumors (13) and pediatric tumors (14) . Although a metagene was defined for each human malignancy, projected clustering could not entirely separate human ARMS and ERMS ( Supplementary Fig. S3A ). In addition to our six cases of mouse ARMS samples, published mouse osteosarcoma samples (15) and mouse medulloblastoma samples (16) were used as testing samples. The projected clustering of mouse tumors showed mouse ARMS cluster with human rhabdomyosarcomas (both ARMS and ERMS) and mouse osteosarcomas and medulloblastomas cluster with their human counterparts. Another metagene analysis was performed using a well-characterized data set of human rhabdomyosarcoma (9) . Again, however, a defined metagene failed to separate human ARMS and human ERMS completely; instead, 7 of 22 human ARMS clustered with human ERMS ( Supplementary   Fig. S3B ). Hierarchial clustering after metagene projection showed that mouse ARMS cluster with those seven cases of human ARMS, which confirmed that mouse ARMS recapitulates, at least, a subset of human ARMS cases.
The previous literature (8, 9, 23) has identified a subset of genes, which are specifically overexpressed in human ARMS compared with ERMS. Lae and colleagues (9) compared those gene sets and identified 11 genes that are shared in all of those three publications. To further validate that the mouse tumors share the genetic features of human ARMS, expression of those 11 genes, as well as Mycn, another representative alveolar specific gene, were examined by qRT-PCR (Fig. 4) among those 12 genes, nine genes (Ass1, Cnr1, Dcx, Ela1, Foxf1a, Pipox, Tcfap2b, Wscd1, and Mycn) were significantly overexpressed compared with skeletal muscle. Thus, collectively, mouse ARMS tumors share a common core expression profile with human ARMS tumors.
Cross-species comparison of mouse and human Pax3:Fkhrpositive ARMS identifies a conserved expression signature of ARMS and permits Pax3:Fkhr target identification. To identify a conserved molecular profile of ARMS across species, genes differentially expressed in mouse tumors compared with WT skeletal muscle were projected into human rhabdomyosarcoma versus skeletal muscle. For the human data, published data sets of human young, old, and pathologic skeletal muscle (10, 11) and human rhabdomyosarcoma (8) were used. Genes (1,624) were differentially expressed in mouse ARMS versus skeletal muscle (673 up-regulated genes and 951 down-regulated genes in mouse ARMS; Supplementary Table S8) . Among those 1,624 genes, 1,046 genes (392 of 673 up-regulated genes and 654 of 951 downregulated genes) were also differentially expressed in human ARMS (P < 0.01 by t test in tumors of both species compared with skeletal muscle; Supplementary Fig. S4A ). This list may be a mixture of tumor-related and non-tumor-related genes, especially knowing that in vivo studies have shown that Pax3:Fkhr can not only cause tumors but also lead to abnormally developed, disordered (dystrophic) muscle (7, 24) . Therefore, we sought to enrich for tumor-specific genes by excluding genes differentially expressed by diseased muscle, thus highlighting 368 genes in the cross-species molecular profile of ARMS (158 up-regulated and 210 downregulated genes; Supplementary Table S8) .
Using a different approach, we went on to identify a Pax3:Fkhr molecular signature conserved across species by combining the 1,624 mouse genes differentially expressed between mouse ARMS with the set of human Pax3:Fkhr-positive ARMS versus fusionnegative ARMS (P < 0.01; Supplementary Fig. S3B ; gene list in Supplementary Table S10 ). Fifty-six intersecting genes were identified, which may be Pax3:Fkhr direct or indirect transcriptional targets.
Among those genes was SKP2, whose expression has been reported to be up-regulated by Pax3:Fkhr (25) . The overexpression of SKP2 gene in both mouse and human fusion-positive rhabdomyosarcoma was confirmed by qRT-PCR ( Supplementary  Fig. S3C ). To determine whether SKP2 transcription is regulated by Pax3:Fkhr, NIH3T3 cells were infected with a retrovirus carrying Pax3:Fkhr and then treated with cycloheximide for up to 8 hours (Fig. 5A) . Treatment with cycloheximide did not affect SKP2 levels during this time course, suggesting that SKP2 transcription may be directly regulated by Pax3:Fkhr. To further study whether SKP2 is a direct transcriptional target of Pax3:Fkhr, a reporter assay was performed using the SKP2 promoter (Fig. 5B) . Serially deleted genomic fragments from the SKP2 promoter region (spanning the 3723bp fragment 5 ¶ upstream of SKP2) were tested for the response to Pax3:Fkhr overexpression in NIH3T3 cells. However, the SKP2 promoter fragments did not show a transcriptional response to Pax3:Fkhr, although the SKP2 promoter did respond to E2F1, a known direct transcription activator of SKP2 gene ( Fig. 5B; ref. 17) .
Whereas the proximal 3.7kb SKP2 promoter had no activity in response to Pax3:Fkhr, we speculated that Pax3:Fkhr may be upregulating SKP2 through another cis-element. In keeping with this hypothesis, Barber and colleagues reported from a chromatin immunoprecipitation screen that Pax3:Fkhr can bind to a 220-bp genomic fragment, which is 49 kb downstream (3 ¶) to the SKP2 gene transcription initiation site (Supplementary Fig. S5; ref. 26 ). The distance, albeit long, is not unprecedented for genes involved in myogenic programming (27) .This potential cis-element is conserved across species (Supplementary Fig. S5A ). A reporter assay using this 220-bp genomic fragment showed increased luciferase activity when NIH3T3 cells or p53-deficient MEFs were cotransfected with Pax3:Fkhr, and like the PDGFRA reporter control (18) , p53 may antagonize Pax3:Fkhr-mediated transcriptional activation of the SKP2 cis-element, depending upon the cellular context (antagonism was seen in NIH3T3 cells, but not in p53-deficient MEFs; Fig. 5C ). Thus, this cis-element may be in at least one site by which Pax3:Fkhr regulates SKP2. A definite link between this Pax3:Fkhr responsive element and transcription of the SKP2 gene will likely require future generation of new transgenic animals.
To determine the relevance of SKP2 up-regulation by Pax3:Fkhr, we performed functional studies in human ARMS cells. SKP2 has been reported to be involved in the cell cycle-dependent control of p27 kip1 ubiqitination and, thus, cell cycle entry/tumor cell growth. To determine whether SKP2 repression can affect cell growth, the human ARMS cell line Rh30 was stably transfected with SKP2-specific short hairpin RNA (shRNA), as described previously (ref. 28 ; Fig. 5D Fig. S5B ). Collectively, these data indicate that SKP2 is a potential transcriptional target of Pax3:Fkhr via a 3 ¶ cis-element and that SKP2 plays a major role in the cell proliferation of ARMS. More broadly, these results suggest that the mouse model of ARMS can serve to identify a Pax3:Fkhr molecular signature and Pax3:Fkhr target genes conserved across species.
The mouse model represents a system for evaluating kinase inhibitors for ARMS. This mouse model was previously used to validate a receptor tyrosine kinase, PDGFRA, as a direct transcriptional target of Pax3:Fkhr and therapeutic target (18) . To identify other potential druggable targets in ARMS, we selected a subset of protein kinase genes that were up-regulated in both mouse and human ARMS tumors (Fig. 6A) . Among 19 protein kinases up-regulated in mouse tumors, up-regulation of 16 kinases was conserved in human ARMS. From this set, kinase inhibitors are available against seven genes, including VRK1, AURKB, PLK2, PLK4, CDK4, CHEK1, and TK1 (29) (30) (31) . Overexpression of these kinases was confirmed by qRT-PCR in a larger set of mouse tumors (Fig. 6B) . These results validate the future use of this mouse model as a preclinical tool for the study of therapeutic kinase inhibitor strategies in ARMS. 
Discussion
In this paper, we present a cross-species validation of a genetically engineered mouse model of ARMS. The implicit advantage of using conditional genetic models for preclinical therapeutic testing are that tumors arise in an authentic microenvironment, i.e., skeletal muscle, and that the immune system is intact. The latter may be especially important for the promising cadre of monoclonal antibodies, for which antibody-dependent cellular cytotoxicity may require immunocompetence (32) .
Our study shows that this ARMS model is advantageous for preclinical therapeutics for several reasons. We show that the Pax3:Fkhr, p53 model has 100% penetrance by 150 days (young adulthood in a mouse) with a spectrum of disease sites that are comparable with human rhabdomyosarcoma. Histology and immunohistochemical markers also mimic the human disease, as reported here and previously (5, 7) . Furthermore, the progression of disease in terms of primary tumor growth and extent of disease are as rapid as or more rapid than the human disease, making the model useful for understanding the underlying disease mechanisms that allow unresectable or metastatic rhabdomyosarcoma to elude therapy. We show at a cellular level that cooperative factors other than the Pax3:Fkhr fusion or p53 inactivation are likely to be responsible for Pax3:Fkhr transcriptional regulation in preneoplastic muscle. However, once the primary tumor has formed, tumor cells that metastasize appear to be under selection for Pax3:Fkhr expression. Whereas targeting transcription factors, such as Pax3:Fkhr, is therapeutically challenging, one can hope that cooperative factors that facilitate high Pax3:Fkhr transcription might include cell surface receptors or proteins sensitive to small molecule inhibitors. The identification of these cooperative factors that modulate Pax3:Fkhr expression is the subject of ongoing studies.
To validate our model on a whole-genome basis, we performed a cross-species gene expression analysis. Gene set enrichment analysis confirmed that our model is most related to human ARMS among a variety of human sarcomas. We also performed metagene projection. This powerful method of cross-species, Figure 4 . Expression of human ARMS-specific genes were studied by qRT-PCR in mouse ARMS tumors (n = 10) and skeletal muscles (SKM, n = 6). *, significant difference between mouse tumors and skeletal muscle (P < 0.05). Nine of 12 genes were significantly overexpressed in mouse tumors compared with skeletal muscle.
cross-platform analysis (22) has been used recently to compare mouse and human pediatric cancer models among a variety of cancer subtypes. However, this method warrants some caution because results are dependent upon a training set with a large homogeneous collection of each tumor subtype. For rhabdomyosarcomas, which are relatively rare, sample size has been problematic in other studies (15) . Nevertheless, we were able to show that, compared with other pediatric cancers, our mouse model is most similar to human rhabdomyosarcomas and specifically human ARMS. We found, however, that despite using the best available microarray data set for rhabdomyosarcoma subtypes, metagene analysis could no better separate human Pax:Fkhr-positive ARMS from ERMS than the original report for this data set (9) . This result may be due to a technical limitation of this approach and a small sample size or may suggest that ARMS and ERMS (as defined by histology) may be a continuous spectrum of disease. This later possibility, taken in a positive light, suggests that rhabdomyosarcomas might still be further subclassified on We went on to identify 368 tumor-specific genes in common between mouse and human tumors that could neither be explained as being related to a normal muscle or degenerative muscle phenotype. Next, we used this genetic model to identify potential downstream targets of Pax3:Fkhr. Identifying Pax3:Fkhr targets has been the subject of numerous antecedent studies using many different valid approaches (i.e., transfection of rhabdomyosarcoma or nonrhabdomyosarcoma cells with Pax3:Fkhr, comparison between primary tumors, or combinations thereof; refs. 23, 26, 32-37). Our approach is meant only to be complementary. In the end, primary human tumor samples (Pax3:Fkhr-positive versus fusion-negative ARMS) are the definitive study set for such determinations, but getting large numbers of high-quality rapidly processed samples of these rare tumors has been a challenge for the field. Nevertheless, our cross-species approach identified 56 candidate target genes of Pax3:Fkhr, including SKP2 (Fig. 5A, right) . SKP2 has been suggested to be a target gene of Pax3:Fkhr, but not Pax3, in fibroblasts (25) . We have extended this result by validating SKP2 as a Pax3:Fkhr target in vivo. SKP2 is a component of the SCF (SKP1-CUL1-F-box) protein complex that mediates the ubiquitination and proteasomal degradation of cell cycle regulatory genes, including p27 (25, 38) , thereby accelerating cell cycle progression. Ironically, SKP2 also interacts with and promotes the ubiquitinmediated degradation of Fkhr (FoxO1A; ref. 39 ). This SKP2-mediated degradation of Fkhr requires phosphorylation of Fkhr at Ser-256 (39), which is in fact retained by Pax3:Fkhr (40) . Interestingly, Fkhr Ser-256 phosphorylation also reduces binding of Fkhr to DNA and causes nuclear exclusion of Fkhr when Thr-24 and Ser-319 are also phosphorylated (41) . The extent to which the phosphorylation of this serine residue in Pax3:Fkhr can be enforced to take advantage of SKP2 overexpression, SCF-mediated degradation, and Pax3:Fkhr nuclear exclusion is the topic of the ongoing investigation.
To identify new therapeutic targets, we examined the expression of potentially ''druggable'' kinases. The range of available kinase inhibitors is growing rapidly; therefore, we examined the crossspecies rhabdomyosarcoma expression of kinases known to have an inhibitor available preclinically or clinically. We identified seven kinases, including an aurora kinase and two polo-like kinases.
For all of the strengths of this five allele genetically engineered model (more alleles if you include reporter genes for noninvasive imaging), significant infrastructure investments are required to maintain this disease model system. Because tumors can arise from deep sites, specialized small animal imaging technology is necessary (42) because traditional measurement with calipers at the skin surface nearly always underestimates the extent of disease. Luciferase has been suprisingly noninformative in our model system because tumors have a tendency to be centrally hypovascular and hypoxic (42) , thereby unable to have access to the oxygen required by luciferase. 15 The financial investment in maintaining mouse stock lines, husbandry, and genotyping is also nontrivial; therefore, alternative models, such as very successful rhabdomyosarcoma xenograft systems (43) and a recently reported ectopic allograft model (44) , are warranted options to our transgenic model. In some instances, certain targets identified from human tumors are not expressed in the cell lines used for xenografts (18) . In these cases, the genetically engineered model may not only be essential but also extremely productive. Our laboratory recently identified PDGFRA as a potential therapeutic target from the study of the ARMS preclinical model we report here (18) . To follow this example and to make our model more practical for widespread use, we will be soon participating in the National Cancer Institute Pediatric Preclinical Testing Program (45, 46) , with the intent of examining efficacy of novel targeted therapies. We will also be providing preclinical testing for outside investigators on a high-volume, low-cost basis. In this cooperative framework, the outlook for new therapies in ARMS may be significantly improved. 
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